ArticleThe journal of obstetrics and gynaecology research2026
Neoadjuvant Paclitaxel-Carboplatin Chemotherapy Followed by Cesarean Radical Hysterectomy in Pregnant Patients With Cervical Cancer: Obstetric, Neonatal, and Surgical Outcomes.
Article in The journal of obstetrics and gynaecology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate pregnancy, peripartum, neonatal, and oncologic outcomes in pregnant patients with cervical cancer treated with neoadjuvant paclitaxel-carboplatin chemotherapy followed by cesarean radical hysterectomy (CRH).
methodsThis retrospective single-center study included nine pregnant women diagnosed with histologically confirmed cervical cancer during pregnancy who received neoadjuvant chemotherapy and subsequently underwent CRH between 2011 and 2023. Maternal clinical characteristics, chemotherapy-related toxicities, surgical outcomes, placental pathology, and neonatal outcomes were reviewed. Disease-free survival and overall survival were descriptively assessed.
resultsThe median gestational age at diagnosis was 14.1 weeks (range, 4.2-28.1 weeks). All patients received paclitaxel-carboplatin chemotherapy after the first trimester (median, three cycles). The median gestational age at CRH was 33.5 weeks (range, 30.6-36.3 weeks). Median estimated blood loss was 1800 mL, and most patients required perioperative transfusion. Placental examination frequently demonstrated maternal underperfusion. One infant was small for gestational age, and most neonates were admitted to the NICU for prematurity-related monitoring; all complications resolved without long-term sequelae. During a median follow-up of 62 months, no recurrence or death was observed.
conclusionNeoadjuvant paclitaxel-carboplatin chemotherapy followed by CRH allowed continuation of pregnancy until delivery in this small cohort of patients with cervical cancer during pregnancy. Despite frequent NICU admission, prematurity-related complications, and substantial surgical morbidity, neonatal complications were mostly transient and long-term oncologic outcomes appeared reassuring. These findings support the feasibility of this multidisciplinary treatment approach in carefully selected patients who wish to continue their pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.